Abstract
BackgroundAssessment of the seriousness, expectedness and causality are necessary for any adverse event (AE) in a clinical trial. In addition, assessing AE severity helps determine the importance of the AE in the clinical setting. Standardisation of AE severity criteria could make safety information more reliable and comparable across trials. Although standardised AE severity scales have been developed in other research fields, they are not suitable for use in neonates. The development of an AE severity scale to facilitate the conduct and interpretation of neonatal clinical trials is therefore urgently needed.MethodsA stepwise consensus process was undertaken within the International Neonatal Consortium (INC) with input from all relevant stakeholders. The consensus process included several rounds of surveys (based on a Delphi approach), face-to-face meetings and a pilot validation.ResultsNeonatal AE severity was classified by five grades (mild, moderate, severe, life threatening or death). AE severity in neonates was defined by the effect of the AE on age appropriate behaviour, basal physiological functions and care changes in response to the AE. Pilot validation of the generic criteria revealed κ=0.23 and guided further refinement. This generic scale was applied to 35 typical and common neonatal AEs resulting in the INC neonatal AE severity scale (NAESS) V.1.0, which is now publicly available.DiscussionThe INC NAESS is an ongoing effort that will be continuously updated. Future perspectives include further validation and the development of a training module for users.
Funder
Agentschap voor Innovatie door Wetenschap en Technologie
US Food and Drug Administration
Subject
Pediatrics, Perinatology and Child Health
Reference28 articles.
1. Abraham J . International Conference On Harmonisation Of Technical Requirements For Registration Of Pharmaceuticals For Human Use. In: Handbook of transnational economic governance regimes. Brill, 2009: 1041–54.
2. Center for Drug Evaluation and Research . Investigational New Drug (IND) Application - Final Rule: Investigational New Drug Safety Reporting Requirements for Human Drug and Biological Products and Safety Reporting Requirements for Bioavailability and Bioequivalence Studies in Humans. Available: https://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/InvestigationalNewDrugINDApplication/ucm226358.htm [Accessed 1 Dec 2018].
3. Center for Devices and Radiological Health . Medical Device Databases - Code of Federal Regulations - Title 21 - Food and Drugs. Available: https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/Databases/ucm135680.htm [Accessed 1 Dec 2018].
4. Stoll BJ , Hansen NI , Bell EF , et al . Trends in care practices, morbidity, and mortality of extremely preterm neonates, 1993-2012. JAMA 2015;314.doi:10.1001/jama.2015.10244
5. FDA . Guidance to industry and Investigaors: safety reporting requirements for IND and BA/BE. Available: https://www.fda.gov/downloads/Drugs/Guidances/UCM227351.pdf
Cited by
47 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献